Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)

• Company Description    Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $1.42 Daily Weekly Monthly 20 Day Moving Average: 417,226 shares Shares Outstanding: 3.63 (millions) Market Capitalization: $5.18 (millions) Beta: 1.15 52 Week High: $10.96 52 Week Low: $1.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.16% -32.07% 12 Week -32.14% -34.09% Year To Date -82.49% -85.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7946 IVANHOE AVENUE SUITE 201 - LA JOLLA,CA 92037 USA ph: 858-263-4196 fax: - shannon@mzgroup.us http://www.ensysce.com

• General Corporate Information    Officers Lynn Kirkpatrick - Chief Executive Officer; President and Director Bob Gower - Chairman and Director David Humphrey - Chief Financial Officer; Secretary and Treasurer Andrew Benton - Director William Chang - Director Peer Information Ensysce Biosciences, Inc. (CORR.) Ensysce Biosciences, Inc. (RSPI) Ensysce Biosciences, Inc. (CGXP) Ensysce Biosciences, Inc. (BGEN) Ensysce Biosciences, Inc. (GTBP) Ensysce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293602504 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/09/26 Share - Related Items Shares Outstanding: 3.63 Most Recent Split Date: 12.00 (0.07:1) Beta: 1.15 Market Capitalization: $5.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.99 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.83 Price/Cash Flow: - Price / Sales: 1.15 EPS Growth vs. Year Ago Period: -222.92% vs. Previous Quarter: -63.29% Sales Growth vs. Year Ago Period: -85.58% vs. Previous Quarter: -64.04% ROE 09/30/25 - -437.31 06/30/25 - -167.23 03/31/25 - -192.54 ROA 09/30/25 - -231.45 06/30/25 - -104.59 03/31/25 - -121.77 Current Ratio 09/30/25 - 1.27 06/30/25 - 2.10 03/31/25 - 2.50 Quick Ratio 09/30/25 - 1.27 06/30/25 - 2.10 03/31/25 - 2.50 Operating Margin 09/30/25 - -244.47 06/30/25 - -88.76 03/31/25 - -109.49 Net Margin 09/30/25 - -244.47 06/30/25 - -88.76 03/31/25 - -109.49 Pre-Tax Margin 09/30/25 - -244.50 06/30/25 - -88.78 03/31/25 - -109.49 Book Value 09/30/25 - 0.29 06/30/25 - 1.29 03/31/25 - 1.15 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©